Search the Newsreel

NeuroPace Q2 Earnings Call Highlights

NeuroPace reported strong Q2 revenue growth driven by its RNS System for adult focal epilepsy, leading to a raised full-year revenue and adjusted EBITDA outlook. The company is also engaging with the FDA regarding expanding the RNS System's indication to idiopathic generalized epilepsy (IGE), …

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based …

NeuroPace Q2 2026 slides: 21% RNS growth, $55B+ market opportunity

NeuroPace reported strong Q2 2026 results with 21.3% year-over-year revenue growth in its RNS System business, driven by increasing adoption in the adult focal epilepsy market. Despite beating analyst estimates, shares declined due to ongoing losses and regulatory uncertainty surrounding its idiopathic generalized epilepsy …

NeuroPace Raises FY26 Sales Guidance Above Estimates

NeuroPace Inc. has increased its sales guidance for fiscal year 2026 to $99.5 million-$101.5 million, surpassing the consensus estimate of $99.913 million. This upward revision indicates strong demand for its RNS System and improved visibility into recurring revenue, demonstrating the company's confidence in its …

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace, Inc. reported its second-quarter 2026 financial results, with total revenue reaching $22.8 million and RNS revenue growing 21% to $22.5 million. The company raised its full-year 2026 total revenue guidance to $99.5 million to $101.5 million and improved its Adjusted EBITDA loss. NeuroPace …

NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours

NeuroPace reported Q2 2026 results that exceeded Wall Street expectations for both earnings and revenue, but its shares fell in after-hours trading. The company posted a narrower adjusted loss and 17% revenue growth, driven by strong RNS System sales. Management raised full-year revenue and …

Neuropace earnings beat by $0.03, revenue topped estimates

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace, Inc. (NPCE) reported a Q2 loss of $0.18 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and showing an improvement from a $0.26 loss a year ago. The company also surpassed revenue estimates, posting $22.83 million against a consensus of …

NeuroPace Inc 2Q 2026: Revenue $22.8M, Net loss $(6.2M), EPS $(0.18) — 10-Q Summary

NeuroPace Inc reported its second-quarter 2026 results, showing a revenue of $22.8 million, a 17% increase year-over-year. The company posted a net loss attributable to common stockholders of $(6.2) million, with a diluted loss per share of $(0.18), an improvement from $(0.26) in the …

NeuroPace Inc.: Q2 Earnings Snapshot

NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview

NeuroPace, Inc. is projected to report a loss of 21 cents per share, according to this earnings preview. The article indicates that this financial outlook is based on information from Refinitiv. Full article access requires a TradingView subscription.

Enterprise value to EBIT forward of Neuropace, Inc. – NASDAQ:NPCE

This article provides a financial data point for Neuropace, Inc. (NASDAQ: NPCE), specifically its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, indicating the company's financial metrics. The content is sparse, primarily focusing on this single financial ratio …

Neuropace Inc (NPCE) Stock News Today

This page from TradingKey provides current stock information for Neuropace Inc (NPCE), including its stock price, market cap, and links to financial data, forecasts, and ownership details. As of the latest update, the stock was trading at $14.830, up 6.69%, with a market cap …

Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11

This article announces that NeuroPace is scheduled to release its financial results after the market closes on August 11. Investors and analysts will be keen to review the company's performance and outlook during the upcoming earnings call.

NeuroPace (NPCE) Expected to Release Earnings on Tuesday

NeuroPace (NPCE) is scheduled to release its Q2 2026 earnings after market close on Tuesday, August 11th. Analysts anticipate a loss of $0.19 per share on revenue of $22.6 million. In the previous quarter, the company surpassed estimates with a loss of $0.13 per …

NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has received a "Moderate Buy" consensus recommendation from ten analysts, with an average 12-month price target of $19.29, significantly above its recent opening price of $13.50. The company recently surpassed earnings expectations, reporting a smaller adjusted loss and higher revenue than …

Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis

Neuropace Inc (NPCE) currently holds a financial score of 6.68, ranking 138 out of 200 in the Healthcare Equipment & Supplies industry, indicating a weak financial status and average operating efficiency. The company's latest quarterly revenue decreased by 2.02% year-over-year to $22.07M, with net …

Price to book forward of Neuropace, Inc. – NASDAQ:NPCE

This page provides financial information for Neuropace, Inc. (NASDAQ: NPCE), specifically focusing on its price to book forward ratio. It includes links to various financial data, news, and community sections related to the company on the TradingView platform.

Trading the Move, Not the Narrative: (NPCE) Edition

This article provides an AI-driven analysis of Neuropace Inc. (NPCE), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis emphasizes elevated downside risk …

Neuropace, Inc. Revenue Breakdown – NASDAQ:NPCE

Neuropace, Inc. (NASDAQ: NPCE) generated $99.99 million in revenue last year, primarily from its Medical Device segment, which contributed the entire amount. This marks an increase from $79.91 million in the previous year. The United States was the company's largest market, accounting for all …

Neuropace Inc (NPCE) Institutional Confidence

Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, ranking 1st out of 199 in its industry. The institutional shareholding proportion is 99.26%, showing a 7.21% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.51% of outstanding shares.

Cantor Fitzgerald Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $21

Cantor Fitzgerald has initiated coverage on NeuroPace (NPCE.US) with a Buy rating. The firm also announced a price target of $21 for NeuroPace's stock.

Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Neuropace Inc (NPCE), focusing on its support and resistance levels, key indicators, and moving averages. NPCE's current price momentum score is 4.49, and it is trading between a resistance level of 16.77 and a support level of …

H.C. Wainwright reiterates Buy on NeuroPace stock after FDA feedback

H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for NeuroPace Inc (NASDAQ:NPCE) despite the FDA not approving its Premarket Approval Supplement in its current form. The FDA is requesting additional clinical evidence but has provided a path forward for potential …

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data

NeuroPace's premarket approval supplement to expand the RNS System's use for idiopathic generalized epilepsy (IGE) has been deemed "not approvable" by the FDA, which is requesting more clinical evidence. The company plans to submit a Submission Issue Request to discuss its response with the …

HC Wainwright Reaffirms Buy Rating for NeuroPace (NASDAQ:NPCE)

HC Wainwright has reaffirmed its "Buy" rating for NeuroPace (NASDAQ:NPCE), setting a price target of $20.00, suggesting a 30.63% upside. NeuroPace exceeded quarterly earnings expectations, reporting a loss of $0.13 per share against an estimated $0.19 loss, and revenues of $22.0 million, slightly above …

NeuroPace's Panel Track Supplement Not Approvable in Current Form, FDA Says

NeuroPace (NASDAQ: NPRC) announced that the FDA has informed the company that its Panel Track Supplement for the RNS System is not approvable in its current form. The company plans to request a meeting with the FDA to discuss the path forward, indicating a …

FDA Asks NeuroPace for More Evidence on Epilepsy Device

NeuroPace (Nasdaq: NPCE) announced that its Premarket Approval Supplement for expanding the RNS® System's indication to include idiopathic generalized epilepsy was deemed "not approvable in its current form" by the FDA. The FDA requested additional clinical evidence from the NAUTILUS trial and supporting literature. …

NeuroPace stock tumbles as FDA declines epilepsy expansion

NeuroPace (NASDAQ:NPCE) shares dropped by 14.9% after the FDA did not approve its application to expand the RNS System's indication for idiopathic generalized epilepsy, requesting additional clinical evidence. The company plans to submit a Submission Issue Request and amend its application with more data …

Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Neuropace Inc (NPCE), showing its current valuation score is 9.44, ranking 19th in its industry. The company's P/E ratio is -23.72, falling between its recent high and low. Other key valuation metrics like P/B, P/S, and P/CF …

Neuropace Inc (NPCE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Neuropace Inc (NPCE). It states that Neuropace Inc has distributed a total of $0.00 in dividends over the past 5 years and indicates that no further data is available regarding specific dividend …

Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Neuropace Inc (NPCE), focusing on business segments and regional revenue and profit contribution. It notes that relevant data for these breakdowns, particularly by business segment, have not yet been disclosed by the company, though it lists United …